Medical

Savara Pharmaceuticals has presented interim results from a Phase 2 study of Aironite sodium nitrite inhalation solution for the treatment of pulmonary hypertension at the 4th Annual Drug Discovery and Development Symposium for Pulmonary Hypertension. Savara acquired Aironite when Mast Therapeutics merged with the company earlier this year. Mast had acquired … [Read more...] about Positive interim results from Phase 2 study of Aironite for pulmonary hypertension

Windtree Therapeutics has announced that its Phase 2b clinical trial of Aerosurf aerosolized KL4 surfactant for the treatment of respiratory distress syndrome (RDS) in premature infants receiving nasal continuous positive airway pressure (nCPAP) failed to meet its primary endpoint, reduction in nCPAP failure at 72 hours. The study enrolled 221 infants that received … [Read more...] about Phase 2b trial of Aerosurf inhaled surfactant for RDS fails to meet primary endpoint

The AIR Louisville program, which distributed Propeller Health's inhaler monitoring technology to asthma and COPD patients in Louisville, Kentucky, has announced its final results. Beginning in 2015, the program enrolled 1,147 patients and captured data on over 250,000 inhaler puffs. According to AIR Louisville, participants using the Propeller reduced their use of … [Read more...] about AIR Louisville results show 82% reduction in rescue inhaler use

Sun Pharma Advanced Research Company Ltd. (SPARC) has announced that its SPARC DPI salmeterol 25 µg/fluticasone propionate 50 µg dry powder inhaler failed to show bioequivalence to Seretide Accuhaler (Advair Diskus) salmeterol 50 µg/fluticasone propionate 100 µg in a pivotal study because the peak concentration of salmeterol for patients using the SPARC DPI was higher … [Read more...] about SPARC announces top line results of pivotal trial of SPARC DPI, a generic version of Seretide Accuhaler/Advair Diskus

German biotech Ventaleon, a spin-off of Activaero, which was acquired by Vectura in 2014, presented data from a Phase 2 trial of inhaled D, L-lysine acetylsalicylate glycine (LASAG) in severe influenza at the recent ISAM Congress that show inhibition of a signaling factor required for flu virus replication. The double-blind placebo-controlled study, in 41 … [Read more...] about Ventaleon presents data from Phase 2 study of inhaled LASAG for severe influenza

Dr. Reddy's subsidiary Promius Pharma has announced that a Phase 2 study of its DFN-02 intranasal sumatriptan for the treatment of migraine met its primary endpoint, the proportion of subjects free of migraine pain at 2 hours post dose. After 2 hours, 43.8% of patients treated with DFN-02 experienced migraine pain relief compared to 22.5% of patients who received … [Read more...] about Phase 2 study of Promius Pharma’s intranasal sumatriptan meets primary endpoint

InCarda Therapeutics has announced that a Phase 1 study of InRhythm inhaled flecainide, which it is developing for the treatment of paroxysmal atrial fibrillation (PAF), met its primary and secondary endpoints, with all doses found to be safe and well tolerated and achieving effective plasma levels within 3 minutes. In 2015, InCarda established an Australian … [Read more...] about InCarda announces positive Phase 1 results for inhaled flecainide

Vectura has announced that it is presenting positive results from a Phase I clinical study of VR942, an inhaled anti-IL-13 monoclonal fragment antibody, at the American Thoracic Society 2017 International Conference. Vectura is partnered with UCB to develop VR942 as a treatment for severe asthma, and the companies expect to begin a Phase 2 study in the second half of … [Read more...] about Vectura reports positive Phase 1 results for VR942 inhaled biologic